Several lines of evidence have suggested that COX-2 expression is increased in NSCLC, especially adenocarcinoma [9,10,11], and that higher COX-2 expression levels are associated with worse outcomes [10,12]. The gene discussed is PTGS2; the disease is adenocarcinoma.